15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Arrowhead Pharmaceuticals Inc, 9 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $46.00 to $110.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $88.75 sits 3% above the current $85.77. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees revenue growth near -43% this year and -29% next, consensus EPS building from about $-1.17 next quarter toward $-4.56 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy975%
Hold325%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Arrowhead Pharmaceuticals Inc.
As of Jul, 9 of 12 firms rate ARWR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARWR EPS & revenue forecast
EPS · NEXT QUARTER
$-1.17
Range $-1.63 – $-0.35 · 11 analysts · +552% YoY
Next period, 11 analysts expect Arrowhead Pharmaceuticals Inc to earn $-1.17 a share (range $-1.63 – $-0.35), versus $-0.18 a year earlier. Full-year consensus is $-3.08, growing to $-4.56 the year after.
REVENUE · NEXT QUARTER
$76.4M
Range $4.5M – $177.7M · 11 analysts · -69% YoY
Revenue is expected to reach $76.4M (range $4.5M – $177.7M), -69.0% year-over-year. Full-year consensus is $442.3M, rising to $324.5M next year.
Top analysts covering Arrowhead Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARWR.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$38.00-55.7% to target
Overall win rate
53%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #130
Buy
$90.00+4.9% to target
Overall win rate
41%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #136
Buy
$93.00+8.4% to target
Overall win rate
46%
+ Follow
#4
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$100.00+16.6% to target
Overall win rate
35%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$110.00+28.2% to target
Overall win rate
29%
+ Follow
ARWR stock forecast FAQ
What is ARWR's average 12-month price target?+
The 12 analysts with a live target average $88.75 for Arrowhead Pharmaceuticals Inc over the next 12 months, ranging from a $110.00 high to a $46.00 low.
Is ARWR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 9 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARWR?+
The Street-high target is $110.00 (Piper Sandler), and the Street-low is $46.00 (Bernstein). The average of all 12 active targets is $88.75.
How many Wall Street analysts cover ARWR?+
12 analysts have an active rating on Arrowhead Pharmaceuticals Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARWR?+
Among analysts who currently cover ARWR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $38.00 target.
What is Arrowhead Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-1.17 per share (range $-1.63 – $-0.35) across 11 analysts. Full-year EPS is projected at $-3.08, rising to $-4.56 the following year.
How much revenue is Arrowhead Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $76.4M (range $4.5M – $177.7M). Full-year revenue is projected at $442.3M, growing to $324.5M next year.
Have analysts been upgrading or downgrading ARWR lately?+
As of Jul, 9 of 12 firms rate ARWR a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARWR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
